|
|
Post by tingtongtung on Aug 4, 2023 0:26:07 GMT -5
|
|
|
|
Post by cedafuntennis on Aug 4, 2023 2:34:27 GMT -5
I see zero impact as Cipla has not contributed anything to bottom line to date. Not only bottom line, but image wise also zero.
|
|
|
|
Post by akemp3000 on Aug 4, 2023 5:16:12 GMT -5
IMO, there are dots that could be connected with this proposed offer. While nothing much has come of the Cipla agreement to date, players such as Blackstone know what's coming long before retail investors. Their taking controlling interest in Cipla would not likely be any significant impact to Mannkind just yet but it could foreshadow good things coming.
|
|
|
|
Post by prcgorman2 on Aug 4, 2023 6:31:03 GMT -5
At first glance I got excited thinking Blackstone was the largest institutional investor in MannKind. Blackrock, not Blackstone, is the largest institutional investor in MannKind. The article is interesting because of the implication Blackstone can acquire a controlling interest in Cipla. If I were to try to connect the dots (between the Blackstone investment in Cipla and Afrezza trial to get Indian regulatory approval for Cipla to sell Afrezza), it would be that Blackstone expects to be able to capitalize on the quality and convenience of Afrezza as a mealtime insulin in one of the largest Type 2 diabetes populations in the world. Is that on their minds? Frankly, I would be surprised. Delighted actually.
|
|
|
|
Post by veritasfiliatemporis on Aug 4, 2023 7:06:00 GMT -5
At first glance I got excited thinking Blackstone was the largest institutional investor in MannKind. Blackrock, not Blackstone, is the largest institutional investor in MannKind. The article is interesting because of the implication Blackstone can acquire a controlling interest in Cipla. If I were to try to connect the dots (between the Blackstone investment in Cipla and Afrezza trial to get Indian regulatory approval for Cipla to sell Afrezza), it would be that Blackstone expects to be able to capitalize on the quality and convenience of Afrezza as a mealtime insulin in one of the largest Type 2 diabetes populations in the world. Is that on their minds? Frankly, I would be surprised. Delighted actually. Don't be excited no way Mannkind will be sold... maybe 4/5 years Mannkind will get Sanofi....   |
|
|
|
Post by akemp3000 on Aug 4, 2023 7:29:48 GMT -5
At first glance I got excited thinking Blackstone was the largest institutional investor in MannKind. Blackrock, not Blackstone, is the largest institutional investor in MannKind. The article is interesting because of the implication Blackstone can acquire a controlling interest in Cipla. If I were to try to connect the dots (between the Blackstone investment in Cipla and Afrezza trial to get Indian regulatory approval for Cipla to sell Afrezza), it would be that Blackstone expects to be able to capitalize on the quality and convenience of Afrezza as a mealtime insulin in one of the largest Type 2 diabetes populations in the world. Is that on their minds? Frankly, I would be surprised. Delighted actually. Doesn't Blackstone also have history with Mannkind? It would be great to learn Afrezza plays any role in future expectations of this deal but I too would be surprised since there are likely many other considerations. The potential market in India is good. Profitability not so much though volume would help costs. Maybe someone else knows what other attraction for Blackstone buying Cipla might be? It sure would help if we had a couple of insiders here  |
|
|
|
Post by cretin11 on Aug 4, 2023 7:52:47 GMT -5
I see zero impact as Cipla has not contributed anything to bottom line to date. Not only bottom line, but image wise also zero. Agree, zero impact is most likely. However, for the reason you state, there’s no downside (for us) to this potential acquisition. |
|
|
|
Post by uvula on Aug 4, 2023 8:18:41 GMT -5
With mnkd there is always a downside. I don't know what it is, but someone will find it.
|
|
|
|
Post by agedhippie on Aug 4, 2023 8:53:50 GMT -5
Blackstone are after the free cash flow. They are getting a stake, maybe up to 60% if they exercise rights they would get from the 33% share. I don't see this will have any impact on Mannkind either way (it's just one of a pile of drugs Cipla handles). I would also not be certain this is a done deal as I can see the Indian government getting involved in this.
|
|
|
|
Post by tingtongtung on Aug 4, 2023 13:10:54 GMT -5
Blackstone are after the free cash flow. They are getting a stake, maybe up to 60% if they exercise rights they would get from the 33% share. I don't see this will have any impact on Mannkind either way (it's just one of a pile of drugs Cipla handles). I would also not be certain this is a done deal as I can see the Indian government getting involved in this. Dont worry @aged.. I have already told the Indian govt that everything is fine, and that the MNKD PB has checked it and the deal is good.. |
|
|
|
Post by ktim on Aug 4, 2023 17:50:55 GMT -5
At first glance I got excited thinking Blackstone was the largest institutional investor in MannKind. Blackrock, not Blackstone, is the largest institutional investor in MannKind. The article is interesting because of the implication Blackstone can acquire a controlling interest in Cipla. If I were to try to connect the dots (between the Blackstone investment in Cipla and Afrezza trial to get Indian regulatory approval for Cipla to sell Afrezza), it would be that Blackstone expects to be able to capitalize on the quality and convenience of Afrezza as a mealtime insulin in one of the largest Type 2 diabetes populations in the world. Is that on their minds? Frankly, I would be surprised. Delighted actually. Doesn't Blackstone also have history with Mannkind? It would be great to learn Afrezza plays any role in future expectations of this deal but I too would be surprised since there are likely many other considerations. The potential market in India is good. Profitability not so much though volume would help costs. Maybe someone else knows what other attraction for Blackstone buying Cipla might be? It sure would help if we had a couple of insiders here With production of Tyvaso DPI running so high, I doubt CIPLA Afrezza would now move the needle much on COGS % on Afrezza. At this point, short of really good results from the CIPLA trial, they aren't going to make any difference to MNKD's future... no matter who owns them. |
|
|
|
Post by hellodolly on Aug 4, 2023 19:13:15 GMT -5
OK. My turn to offer some conjecture to the board.
What did CIPLA tell Blackstone that have them interested in taking stake, that MNKD hasn't told us?
|
|
|
|
Post by prcgorman2 on Aug 5, 2023 11:00:07 GMT -5
I wonder if Blackstone will attend the Wedbush Pacgrow Healthcare investors conference next week.
|
|
|
|
Post by awesomo on Aug 5, 2023 11:27:45 GMT -5
You guys are acting like Afrezza is a significant portion of Cipla's business.
Cipla had $2.6B in revenue last year. Even in the competely made up scenario where Afrezza get's India approval and sells the same amount as MannKind here ($43M in 2022), that would equate to 1.6% of Cipla's revenue.
Blackstone doesn't care.
|
|
|
|
Post by prcgorman2 on Aug 5, 2023 12:07:01 GMT -5
You misunderstand. I wasn’t suggesting Blackstone gives a hoot about Cipla’s trial they conducted to get Afrezza approved by the India FDA-equivalent regulator, and subsequent anticipation of large sales of Afrezza to India’s enormous population of persons with Type 2 diabetes.
I said if that was the case I would be surprised (flabbergasted would be more accurate) and delighted (overjoyed would be more accurate). I don’t anticipate that happening. It is somewhere between unlikely and exceedingly unlikely. I’m agreeing I don’t think Cipla’s trial of Afrezza to be able to sell Afrezza is an important consideration in Blackstone’s investment in Cipla.
Don’t worry so much. I don’t think any potential retail (or institutional) investors in MNKD are reading this board and getting falsely excited about the possible connection between Cipla, Blackstone, and MannKInd.
However, Blackstone has proven they are interested in investing in BP with promising upsides so it made me wonder if they might be at the Wedbush investment conference next week.
|
|
